1-(2-aminoethyl)cyclopentanamine | 794469-81-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(2-aminoethyl)cyclopentanamine
• 英文别名: 1-(2-Aminoethyl)cyclopentan-1-amine
• CAS: 794469-81-1
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: ZNFLUHAQMSBFJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-aminoethyl)cyclopentanamine 生成 6,8-diazaspiro[4.5]dec-7-en-7-amine
  参考文献：
  名称：

  EP1454909

  摘要：

  公开号：

文献信息

• [EN] SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS SPIROCYCLIQUES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DES RÉCEPTEURS DES CHIMIOKINES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011044197A1

  公开（公告）日：2011-04-14

  The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

  本申请描述了化学式(I)的趋化因子受体活性调节剂，或其立体异构体或药用盐。此外，还披露了使用化学式(I)的调节剂治疗和预防哮喘和过敏病等炎症性疾病，以及类风湿性关节炎和移植排斥等自身免疫病理疾病的方法。
• SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE DERIVATIVES
  申请人：GEORGE Pascal

  公开号：US20080081819A1

  公开（公告）日：2008-04-03

  The invention relates to therapeutic uses of a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. Specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种二氢螺[环烷基]嘧啶酮衍生物或其盐的治疗用途，其化学式如下：其中X、Y、R1、R2、R3、m、n、p和q如本文所述。具体而言，本发明涉及一种药物，包括上述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• Alicyclic diamines, alicyclic diisocyanates and polyisocyanato-isocyanurates and method for the preparation thereof
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0394058A1

  公开（公告）日：1990-10-24

  Herein disclosed are an α-(aminocydonexyl)alkylamine represented by the following general formula (II): wherein R represents hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms, provided that the amino group bonded to the cyclohexyl group may be in either of the 2-, 3- and 4-positions and a method for preparing it; an a-(isocyanatocyclohexyl)alkylisocyanate of Formula (II) wherein the amino groups are replaced with isocyanato groups and a method for preparing it; polyisocyanato-isocyanurate represented by the following general formula (IV): wherein Ri, R2 and R3 may be the same or different and each represents a group represented by the following general formula: wherein R represents hydrogen atom or an alkyl group having 1 to 5 carbon atoms and n is an integer ranging from 1 to 5 and a method for preparing it; and a resin obtained by polymerizing an organic polyisocyanate containing not lower than 10% by weight of the polyisocyanato-isocyanurate represented by Formula (IV) and a compound having at least two active hydrogen atoms as well as a resin composition for coating materials which comprises the resin.

  本发明公开了由以下通式(II)代表的α-(氨基环己基)烷基胺： 其中 R 代表氢原子或具有 1 至 5 个碳原子的低级烷基，但与环己基键合的氨基可位于 2、3 和 4 位中的任一位置；式（II）的 a-(异氰基环己基)烷基异氰酸酯（其中氨基被异氰酸基取代）及其制备方法；由以下通式（IV）表示的聚异氰酸酯： 其中 Ri、R2 和 R3 可以相同或不同，且各自代表下式通式所代表的基团： 其中 R 代表氢原子或具有 1 至 5 个碳原子的烷基，n 为 1 至 5 的整数，以及制备方法；通过聚合有机多异氰酸酯获得的树脂，该有机多异氰酸酯含有不低于 10%（按重量计）的由式(IV)代表的多异氰酸酯和至少具有两个活泼氢原子的化合物，以及包含该树脂的用于涂层材料的树脂组合物。
• Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases
  申请人：SANOFI-SYNTHELABO

  公开号：EP1454909A1

  公开（公告）日：2004-09-08

  The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted; R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; m represents 1 to 4 n represent 0 to 3 p represents 0 to 2 q represents 0 to 2, p+ q being inferior to 4. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及式 (I) 所代表的二氢螺-[环烷基]-嘧啶酮衍生物或其盐： 其中 X 代表两个氢原子、一个硫原子、一个氧原子或一个 C1-2 烷基和一个氢原子； Y 代表键、羰基、任选取代的亚甲基； R1 代表 2、3 或 4-吡啶环或 2、4 或 5-嘧啶环，环可任选被取代； R2 代表苯环或萘环；这些环可任选被取代； R3 代表氢原子、C1-6 烷基或卤素原子； m 代表 1 至 4 n 代表 0 至 3 p 代表 0 至 2 q 代表 0 至 2，p+ q 不如 4。 本发明还涉及一种包含上述衍生物或其盐作为活性成分的药物，该药物用于预防和/或治疗由 GSK3β 活性异常引起的神经退行性疾病，如阿尔茨海默病。
• SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
  申请人：Sanofi-Aventis

  公开号：EP1603915B1

  公开（公告）日：2010-05-26